Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NICOLE SEMINARA

Allopathic & Osteopathic Physicians Dermatology

NPI
1437441003
CMS profile
2784878
Location
HUNTERSVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$457,311.13

589 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 11 of 12; records 501–550 of 589 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NICOLE SEMINARA

NPI 1437441003 · CMS profile ID 2784878

Allopathic & Osteopathic Physicians / Dermatology

HUNTERSVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 11 of 12; records 501–550 of 589 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437441003?year=2024&recipient=provider&page=11#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NICOLE SEMINARA, NPI 1437441003, CMS profile ID 2784878. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 11 of 12; records 501–550 of 589 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437441003?year=2024&recipient=provider&page=11#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). NICOLE SEMINARA, NPI 1437441003, CMS profile ID 2784878. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 11 of 12; records 501–550 of 589 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437441003?year=2024&recipient=provider&page=11#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
NICOLE SEMINARA, NPI 1437441003, CMS profile ID 2784878, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 11 of 12; records 501–550 of 589 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1437441003?year=2024&recipient=provider&page=11#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

589 matching records · $457,311.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 589 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 501–550 of 589.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $765.7602/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078835119 CMS
Janssen Biotech, Inc. $479.5002/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078835168 CMS
Janssen Biotech, Inc. $28.1602/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078321190 CMS
PFIZER INC. $43.5502/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131201186 CMS
ABBVIE INC. $123.0302/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055214 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $20.1702/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152188105 CMS
ABBVIE INC. $33.5102/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055212 CMS
ABBVIE INC. $4,000.0002/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055208 CMS
ABBVIE INC. $45.5602/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055210 CMS
PFIZER INC. $4,150.0002/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131201190 CMS
ABBVIE INC. $34.9102/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055206 CMS
PFIZER INC. $99.0402/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131294559 CMS
ABBVIE INC. $9.4002/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055204 CMS
Dermavant Sciences, Inc. $6.7602/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127930817 CMS
PFIZER INC. $125.0002/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131201182 CMS
ABBVIE INC. $95.4902/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055198 CMS
ABBVIE INC. $727.6602/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055200 CMS
ABBVIE INC. $24.9302/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055202 CMS
Janssen Biotech, Inc. $112.5602/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078834804 CMS
Janssen Biotech, Inc. $41.5402/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078834932 CMS
Lilly USA, LLC $20.4802/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135285472 CMS
PFIZER INC. $2.5402/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131058558 CMS
PFIZER INC. $3.9802/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131148129 CMS
Janssen Biotech, Inc. $3,713.0002/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078835103 CMS
Novartis Pharmaceuticals Corporation $2,750.0002/10/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087179703 CMS
Janssen Biotech, Inc. $125.6302/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078834841 CMS
PFIZER INC. $5.2302/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131149436 CMS
UCB, Inc. $31.3302/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143067529 CMS
ABBVIE INC. $15.8502/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055196 CMS
GENZYME CORPORATION $7.8502/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139831164 CMS
PFIZER INC. $0.7902/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131149231 CMS
PFIZER INC. $6.7602/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131149432 CMS
Janssen Biotech, Inc. $5,775.0002/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078321222 CMS
Dermavant Sciences, Inc. $5.7302/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127930813 CMS
ABBVIE INC. $125.0002/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055192 CMS
ABBVIE INC. $1,083.6502/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055194 CMS
Janssen Biotech, Inc. $28.4702/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078321306 CMS
ABBVIE INC. $4,000.0001/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055186 CMS
ABBVIE INC. $4,000.0001/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055188 CMS
ABBVIE INC. $21.9401/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055190 CMS
Janssen Biotech, Inc. $90.9601/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078835164 CMS
ABBVIE INC. $2.1101/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055180 CMS
ABBVIE INC. $179.7501/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055182 CMS
ABBVIE INC. $5,600.0001/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055184 CMS
ABBVIE INC. $247.8801/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055178 CMS
Dermavant Sciences, Inc. $5.1001/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127930809 CMS
Medimetriks Pharmaceuticals, Inc. $22.9201/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089389677 CMS
ABBVIE INC. $25.1101/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055168 CMS
ABBVIE INC. $378.1501/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055170 CMS
ABBVIE INC. $34.8801/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106055172 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $741.60 8
PY2020 $476.53 14
PY2021 $1,601.96 68
PY2022 $120,861.69 228
PY2023 $295,877.21 464
PY2024 $457,311.13 589
PY2025 $543,711.27 558

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $449,185.29 54
PY2024 Recipient $104.58 1
PY2024 Principal investigator $244,824.63 82
PY2023 Recipient $12,236.00 1
PY2023 Principal investigator $30,566.00 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $254.90 12/31/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS LLC
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202533429
Principal investigator 1 Incyte Corporation $2,480.00 12/19/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571643
Principal investigator 1 Incyte Corporation $3,449.00 12/19/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571654
Principal investigator 1 Incyte Corporation $69.00 12/19/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571684
Principal investigator 1 Incyte Corporation $69.00 12/19/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571690
Principal investigator 1 Incyte Corporation $723.70 12/19/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571726
Principal investigator 1 Incyte Corporation $2,418.00 12/19/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571739
Principal investigator 1 Incyte Corporation $69.00 11/21/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571631
Principal investigator 1 Incyte Corporation $1,495.30 11/21/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571678
Principal investigator 1 Incyte Corporation $2,596.00 11/21/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571698
Principal investigator 1 Incyte Corporation $3,449.00 11/21/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571703
Principal investigator 1 Incyte Corporation $137.00 11/21/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571735
Principal investigator 1 ABBVIE INC. $308.00 11/13/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202524119
Principal investigator 1 SANOFI US SERVICES INC. $3,500.00 11/04/2025 Non-covered Recipient Entity
Onsite Clinical Solutions LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226086259
Principal investigator 1 ABBVIE INC. $4,800.00 10/17/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202517419
Principal investigator 1 ABBVIE INC. $6,516.00 10/09/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202514957
Principal investigator 1 Novartis Pharmaceuticals Corporation $158,940.37 10/08/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS LLC
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190304935
Principal investigator 1 Incyte Corporation $20,000.00 10/02/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571638
Principal investigator 1 Incyte Corporation $3,000.00 10/02/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571651
Principal investigator 1 Incyte Corporation $15,000.00 10/02/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571660
Principal investigator 1 Incyte Corporation $1,500.00 10/02/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571666
Principal investigator 1 Incyte Corporation $1,500.00 10/02/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571672
Principal investigator 1 Incyte Corporation $2,500.00 10/02/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571707
Principal investigator 1 Incyte Corporation $2,500.00 10/02/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571714
Principal investigator 1 Incyte Corporation $2,500.00 10/02/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240571718
Principal investigator 1 ABBVIE INC. $1,948.00 08/06/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202503423
Principal investigator 1 ABBVIE INC. $5,392.00 07/08/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202497494
Principal investigator 1 Eli Lilly and Company $25,217.00 06/16/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187887108
Principal investigator 1 ABBVIE INC. $3,562.57 06/10/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202490743
Principal investigator 1 ABBVIE INC. $2,048.00 06/03/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202488921
Principal investigator 1 ABBVIE INC. $2,400.00 05/08/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202484227
Principal investigator 1 ABBVIE INC. $14,832.00 05/07/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202482457
Principal investigator 1 SANOFI US SERVICES INC. $15,000.00 04/28/2025 Non-covered Recipient Entity
Onsite Clinical Solutions LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226086122
Principal investigator 1 Eli Lilly and Company $4,250.00 04/11/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS LLC
PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB No dispute reported 06/30/2026 1187885232
Principal investigator 1 ABBVIE INC. $4,850.00 04/09/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202475139
Principal investigator 1 ABBVIE INC. $750.00 04/07/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202474696
Principal investigator 1 ABBVIE INC. $5,700.00 04/03/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202471490
Principal investigator 1 ABBVIE INC. $3,544.00 04/03/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202471495
Principal investigator 1 ABBVIE INC. $4,450.89 03/27/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202466626
Principal investigator 1 ABBVIE INC. $7,500.00 03/13/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202463046
Principal investigator 1 ABBVIE INC. $4,250.00 03/07/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202459405
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 02/27/2025 Non-covered Recipient Entity
Onsite Clinic Solutions Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175237961
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 02/27/2025 Non-covered Recipient Entity
Onsite Clinic Solutions Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175237976
Principal investigator 1 Janssen Research & Development, LLC $4,679.00 02/27/2025 Non-covered Recipient Entity
Onsite Clinic Solutions Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175237982
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 02/27/2025 Non-covered Recipient Entity
Onsite Clinic Solutions Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175237990
Principal investigator 1 ABBVIE INC. $500.00 02/18/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202452276
Principal investigator 1 ABBVIE INC. $2,950.00 02/11/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202450526
Principal investigator 1 Janssen Research & Development, LLC $4,679.00 01/29/2025 Non-covered Recipient Entity
Onsite Clinic Solutions Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175237997
Principal investigator 1 Janssen Research & Development, LLC $4,679.00 01/29/2025 Non-covered Recipient Entity
Onsite Clinic Solutions Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175238006
Principal investigator 1 Janssen Research & Development, LLC $1,768.00 01/29/2025 Non-covered Recipient Entity
Onsite Clinic Solutions Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175238935
Principal investigator 1 Eli Lilly and Company $67,755.00 01/28/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187886864
Principal investigator 1 Janssen Research & Development, LLC $344.00 01/24/2025 Non-covered Recipient Entity
Onsite Clinic Solutions Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175237969
Principal investigator 1 Eli Lilly and Company $3,057.56 01/15/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187888858
Principal investigator 1 ABBVIE INC. $4,050.00 01/02/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202434602